Phase 1b/2 study of binimetinib (BINI) in combination with nivolumab (NIVO) or NIVO plus ipilimumab (IPI) in patients (pts) with previously treated microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) with RAS mutation.
Bendell JC. et al, (2018), JOURNAL OF CLINICAL ONCOLOGY, 36
A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424
Woodcock VK. et al, (2018), British Journal of Cancer
ANTI-VCAM-1 TARGETED MRI ALLOWS EARLIER DETECTION OF BRAIN METASTASES IN A XENOGRAFT MELANOMA MOUSE MODEL
Cheng V. et al, (2018), NEURO-ONCOLOGY, 20, 13 - 13
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.
Weber J. et al, (2017), N Engl J Med, 377, 1824 - 1835
Safety, efficacy and biology of the gp100 TCR-based bispecific T cell redirector, IMCgp100 in advanced uveal melanoma in two Phase 1 trials
Carvajal R. et al, (2017), JOURNAL FOR IMMUNOTHERAPY OF CANCER, 5
Clinical trial protocol for TARDOX: a phase I study to investigate the feasibility of targeted release of lyso-thermosensitive liposomal doxorubicin (ThermoDox®) using focused ultrasound in patients with liver tumours.
Lyon PC. et al, (2017), Journal of Therapeutic Ultrasound, 5, 28 - 28
Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.
Petrella TM. et al, (2017), Eur J Cancer, 86, 115 - 124
Societal preferences for adjuvant melanoma health states: UK and Australia.
Middleton MR. et al, (2017), BMC Cancer, 17, 689 - 689
Characterisation of the changing genomic landscape of metastatic melanoma using cell free DNA.
Cutts A. et al, (2017), NPJ genomic medicine, 2, 25 - 25
Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: A randomized, double-blind, phase 3 trial (CheckMate 238)
Weber J. et al, (2017), ANNALS OF ONCOLOGY, 28
Phase I study of the investigational, oral pan-RAF kinase inhibitor TAK580 (MLN2480) in patients with advanced solid tumors (ST) or melanoma (MEL): Final analysis
Olszanski AJ. et al, (2017), ANNALS OF ONCOLOGY, 28
PROCLAIM-CX-2009: A first-in-human trial to evaluate CX-2009 in adults with metastatic or locally advanced unresectable solid tumors
Garcia-Corbacho J. et al, (2017), ANNALS OF ONCOLOGY, 28
Staging gastric cancer with F-18-FDG PET-CT identifies frequent unsuspected metastases and patients at high risk of incurable disease, early recurrence and death
Findlay J. et al, (2017), BRITISH JOURNAL OF SURGERY, 104, 6 - 6
Validation of metabolic nodal response and a simple risk score to predict early recurrence and death after surgery for oesophageal cancer
Findlay J. et al, (2017), BRITISH JOURNAL OF SURGERY, 104, 56 - 57
Erratum to: Ongoing Response in BRAF V600E-Mutant Melanoma After Cessation of Intermittent Vemurafenib Therapy: A Case Report.
Dooley AJ. et al, (2017), Target Oncol, 12
Metabolic nodal response as a prognostic marker after neoadjuvant therapy for oesophageal cancer.
Findlay JM. et al, (2017), Br J Surg, 104
Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Final results for the AVAST-M trial.
Corrie P. et al, (2017), JOURNAL OF CLINICAL ONCOLOGY, 35
A practical application of time to event analysis in the presence of non-proportional hazards
Mohammed SB. et al, (2017)
Metabolic nodal response as a prognostic marker after neoadjuvant therapy for oesophageal cancer.
Findlay JM. et al, (2017), Br J Surg, 104, 408 - 417